11:43 AM EDT, 08/12/2024 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Monday it has been awarded a $2 million grant from the National Institutes of Health's Small Business Innovation Research program for the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma whose disease returned following treatment with anti-CD19 CAR T cell therapy.

The grant will support its phase 1 Apollo study of MT-601, which will enroll up to about 30 participants in the dose escalation phase of the trial, the company said. Including the latest grant, it has secured over $19 million in non-dilutive funding proceeds.

Price: 3.95, Change: +0.14, Percent Change: +3.67